The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S14-S19 , September 2007

Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment

  • Matthew R. Cooperberg

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceuticals.
    • ,
  • Jeannette M. Broering

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceuticals.
    • ,
  • Philip W. Kantoff

      Affiliations

    • Financial interest and/or other relationship with Abbott, Pfizer, Aventis, AstraZeneca, Bristol Myers Squibb, TAP Pharmaceuticals, Amgen, Novartis, Bayer, GlaxoSmithKline, Therion Biologies, Wilex, Genentech and Genzyme.
    • ,
  • Peter R. Carroll

      Affiliations

    • Corresponding Author InformationCorrespondence: University of California-San Francisco/Mt. Zion Cancer Center, 1600 Divisadero St., 3rd Floor, San Francisco, California 94115-1711 (telephone: 415-353-7098; FAX: 415-353-7093).
    • Financial interest and/or other relationship with National Institutes of Health/National Cancer Institute, Department of Defense, TAP Pharmaceuticals, InforMEDical and Strategic Education Physician Academy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0022-5347(07)00823-3

doi: 10.1016/j.juro.2007.03.135

The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S14-S19 , September 2007

Article Tools

* Image Usage & Resolution